Cantor Fitzgerald reiterates Overweight on CytomX stock, $12 target
We haven't written up this one. Investing.com has the full story — the link below goes straight to it.
More in Finance & Markets
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine just cleared a key FDA hurdle with an expanding oncology pipeline behind it.
Why capital, not climate ambition alone, will drive the UAE’s green transition
The global conversation around sustainability is entering a new phase. The question is no longer simply whether governments and businesses should pursue net zero, but rather how the capital required…
Average car loan size jumps 49% to ₹8.2 lakh as buyers shift to SUVs
TransUnion CIBIL data shows average passenger-vehicle loan sizes rose 49 per cent between H1 2019 and H1 2026, while repayment tenures increased by five months to 62 months
Sharjah Islamic Bank’s nine-month profit rises 9% to Dh1.2 billion
Dubai: Sharjah Islamic Bank reported a 9% increase in net profit after tax to Dh1.2 billion for the first nine months of 2026, supported by higher income from Islamic financing and sukuk investments.